Tivantinib: who here thinks this drug isn't an active drug in NSCLC versus this just being a case of incredibly stupid trial design? The way they designed this trial has been argued here many times
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.